United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - salmeterol xinafoate (unii: 6ew8q962a5) (salmeterol - unii:2i4bc502bt) - salmeterol 50 ug - serevent diskus is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with an ics in patients aged 4 years and older with reversible obstructive airway disease, including patients with symptoms of nocturnal asthma. laba, such as salmeterol, the active ingredient in serevent diskus, as monotherapy (without ics) increase the risk of asthma-related death [see warnings and precautions (5.1)] . use of serevent diskus for the treatment of asthma without concomitant use of an ics is contraindicated [see contraindications (4)] . use serevent diskus only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on an ics. do not use serevent diskus for patients whose asthma is adequately controlled on low- or medium-dose ics. pediatric and adolescent patients available data from controlled clinical trials suggest that laba as monotherapy increase the risk of asthma-related hospitalization in pediatric and adolescent pati

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol cip haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg; fluticasone propionate, quantity: 0.25 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include ? patients on effective maintenance doses of long acting beta 2 agonists and inhaled corticosteroids ? patients who are symptomatic on current inhaled corticosteroid therapy for the symptomatic treatment of patients with severe copd (fev1 not more than 50 per cent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta 2 agonist bronchodilator therapy. fluticasone salmeterol multi haler 250/50 is not indicated for the initiation of bronchodilator therapy in copd

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - salmeterol, fluticasone propionate - inhalation powder - salmeterol 50 µg fluticasone propionate 500 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol - pressurised inhalation, suspension - salmeterol 25 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol - inhalation powder, pre-dispensed - salmeterol 50 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 125 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

generics uk limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - salmeterol xinafoate 25 µg; fluticasone propionate 250 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol, fluticasone propionate - pressurised inhalation, suspension - salmeterol 25 µg fluticasone propionate 50 µg - drugs for obstructive airway diseases

Malta - English - Medicines Authority

glaxo smithkline ireland limited 12, riverwalk, citywest business campus, dublin 24, ireland - salmeterol, fluticasone propionate - pressurised inhalation, suspension - salmeterol 25 µg fluticasone propionate 125 µg - drugs for obstructive airway diseases